Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Prelude Therapeutics (NASDAQ: PRLD), a clinical-stage precision oncology company, announced its participation in the Citizens Life Sciences Conference in New York on May 7, 2025. The company's leadership team, including CEO Kris Vaddi, President and CMO Jane Huang, and CSO Peggy Scherle, will engage in a fireside chat at 11:00 a.m. ET. The event will be webcast live on Prelude's website and archived for 90 days. Prelude focuses on developing innovative medicines for cancer patients, with a pipeline including first-in-class SMARCA2 degraders and a CDK9 inhibitor. The company is also advancing Precision ADCs through partnerships.

05/01/2025 - 07:30 AM

WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025.

On Wednesday, May 7, 2025, at 11:00 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Peggy Scherle, Ph.D., Chief Scientific Officer will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.

About Prelude Therapeutics

Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.

Investor Contact:
Robert Doody
Senior Vice President, Investor Relations
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com

FAQ

When is Prelude Therapeutics (PRLD) presenting at the Citizens Life Sciences Conference 2025?

Prelude Therapeutics will present at the Citizens Life Sciences Conference on May 7, 2025, at 11:00 a.m. ET in New York.

Who will be presenting at the PRLD fireside chat at the Citizens Conference?

CEO Kris Vaddi, President and CMO Jane Huang, and CSO Peggy Scherle will participate in the fireside chat.

What are the main products in Prelude Therapeutics' pipeline?

Prelude's pipeline includes first-in-class SMARCA2 degraders (both IV and oral), a CDK9 inhibitor, and Precision ADCs being developed through partnerships.